MDH2-IN-2 is an orally active MDH2 inhibitor with an IC50 of 5.9 μM. MDH2-IN-2 reduces the levels of senescence markers and senescence-associated secretory phenotype (SASP) factors in mammalian cell models. MDH2-IN-2 extends the lifespan and improves the healthspan of *Caenorhabditis elegans*. MDH2-IN-2 alleviates tissue senescence in aged mice, inhibits SASP factors, and restores liver and kidney functions. MDH2-IN-2 is applicable for senescence-related research.

MCULE-3064932370 is a covalent and allosteric SUMO E1 (heterodimer of Aos1 and Uba2) inhibitor with IC50 values ranging from 16.66 μM to 2.96 μM. MCULE-3064932370 inhibits SUMOylation of Uba2. MCULE-3064932370 has anti-cancer activity against breast cancer.

MCH-1623 is a nucleoside analog-derived, RNA-dependent RNA polymerase (RdRP) inhibitor. MCH-1623 interferes with viral RNA synthesis and exhibits broad-spectrum antiviral activity. MCH-1623 effectively inhibits the replication of vesicular stomatitis virus (VSV), influenza A virus (H1N1-PR8), human coronavirus OC43, human metapneumovirus (HMPV) and respiratory syncytial virus (RSV). Administered via inhalation, MCH-1623 exerts significant in vivo activity in mice, reducing pulmonary viral load and IL-6 levels, alleviating pulmonary tissue erythema, and significantly improving the survival rate of mice infected with lethal influenza virus. MCH-1623 can be used to investigate the infection mechanisms of various RNA viruses and for antiviral drug research.

MC-Gly-Gly-Phe-Gly-PAB-MMAE (Compound SMP-81641) is a control targeted linker-agent conjugate. MC-Gly-Gly-Phe-Gly-PAB-MMAE can be used in tumor research.

MC-Gly-Gly-Phe-Gly-cyclopropylacetic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

MC-GGFG-3-Methylenecyclobutyl (compound L-7B) is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mc-Asn-Asn-E104 is a conjugate of E104 and a legumain-cleavable linker, can be used for the synthesis of E104 ISACs.

Mc-Asn-Asn is a legumain cleavable linker for antibody-drug conjugates (ADCs) which couples the antibody element to the effecting compound. Mc-Asn-Asn can be used in the synthesis of ADCs.

Masoprocol tetrapivalate (Nordihydroguaiaretic acid tetrapivalate) is a catecholic butane metabolite and also a tyrosine kinase activity inhibitor of IGF-1R and EGFR. Masoprocol tetrapivalate regulates tyrosine kinase signaling pathways associated with cell proliferation. Masoprocol tetrapivalate can be used in the research of proliferative diseases, including malignant, precancerous or benign cancers, and solid tumors.

MARY15 is a pyridinylpiperazine-based derivative of MARY1. MARY15 activates uncoupled mitochondrial respiration and upregulates p-AKT (S473) phosphorylation in renal proximal tubule cells.

Marpinersen, an antisense oligonucleotide, is an ataxin-2 synthesis reducer. It is used for the study of amyotrophic lateral sclerosis.

Mardepodect precursor is the precursor of Mardepodect. Mardepodect precursor. Mardepodect is a potent, selective orally active, and brain-penetrant PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-fold selectivity over other PDEs.

Mapinastine is a biochemical assay reagent.

MAP3K14-IN-1 (Compound 173) is a MAP3K14 (NIK kinase) inhibitor with an IC50 of 1.8 nM. MAP3K14-IN-1 inhibits the autophosphorylation of MAP3K14 kinase. MAP3K14-IN-1 reduces the level of phosphorylated IKKα in cancer cells. MAP3K14-IN-1 inhibits the proliferation of multiple myeloma cells. MAP3K14-IN-1 can be used in research related to multiple myeloma.

MAO-B-IN-53 is a human monoamine oxidase B (hMAO-B) inhibitor with an IC50 of 0.066 μM. MAO-B-IN-53 exhibits mixed reversible inhibition, binds stably to the hMAO-B active site, and shows high selectivity over hMAO-A. MAO-B-IN-53 acts as a neuroprotective agent, protects against 6-OHDA-induced damage, and exhibits low neurotoxicity in neuroblastoma cells. MAO-B-IN-53 can be used for the research of Parkinson's disease.

MAO-B-IN-50 (Compound C20) is a selective MAO-B inhibitor with an IC50 value of 0.06 μM. MAO-B-IN-50 shows good inhibitory effects on the aggregation of Aβ40/42 and Tau proteins, with overall IC50 values around 1 μM. MAO-B-IN-50 exhibits potent and selective AChE inhibition (IC50 = 1.78 μM). MAO-B-IN-50 can be used in the research of Alzheimer's disease.

MAO-B-IN-49 is a selective and reversible MAO-B inhibitor (IC50 of 1 nM for human MAO-B). MAO-B-IN-49 shows much higher selectivity for MAO-B than for MAO-A (IC50 = 633.9 μM). MAO-B-IN-49 can reduce ROS production induced by Lipopolysaccharides (LPS) in HT22 cells. MAO-B-IN-49 demonstrates substantial neuroprotective properties and significantly improves motor dysfunction in MPTP-induced mouse models of Parkinson’s disease (PD). MAO-B-IN-49 can be used for the study of PD.

Man-GIcNAc-oxazoline (compound 6) is an N-acetylglucosamine (GlcNAc) and azide-modified disaccharide that can be used to label antibodies. Man-GIcNAc-oxazoline can be synthesized as an ADC via click chemistry.

Mal-Pip-ValCit-PAB-AZ7550 is a prodrug of EGFR inhibitor. Mal-Pip-ValCit-PAB-AZ7550 selectively binds covalently to albumin via its maleimide moiety. Mal-Pip-ValCit-PAB-AZ7550 exhibits potent in vivo anticancer activity in non-small cell lung cancer xenograft models. Mal-Pip-ValCit-PAB-AZ7550 can be used in research related to non-small cell lung cancer.

Mal-PEG-NHS ester (MW 2000) is a PEG linker, can be used to link lipoteichoic acid (LTA) and CpG DNA fragments to synthesis CpG-TA Heterodiners. Mal-PEG-NHS ester (MW 2000) can be used for immune stimulation research.

Mal-PEG2-Val-Arg-PABC-OMe-Eribulin (Compound L-1) is a drug-linker conjugate composed of O-Me Eribulin and the linker Mal-PEG2-Val-Cit-PAB-OH. Mal-PEG2-Val-Arg-PABC-OMe-Eribulin can be used to synthesize anti-HER3/MET antibody-drug conjugates (ADCs).

Mal-PEG2-azide is a PEG ADC linker, can be used for ADC synthesis.

Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE (Compound 31) is a Drug-Linker Conjugates for ADC. Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE is composed of MMAE and Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB carbonic acid .

Mafoprazine methanesulfonate is a phenylpiperazine derivative with variable affinities for neuronal receptors. It may exert its antipsychotic effects primarily through D2 receptor blockade and α-adrenergic activity, and may increase the activity of dopamine metabolites.

M4K-2009 is an BBB-penetrant inhibitor of ALK2 with an IC50 of 13 nM. M4K-2009 is an analogue of LDN-214117. M4K-2009 is also active against the hERG potassium channel.

M2WJ332 is an inhibitor of the M2 proton channel of the influenza A virus M2S31N mutant M2. M2WJ332 potently inhibits the influenza A virus A/M2-S31N proton channel in Xenopus laevis oocytes, with an IC50 of 16 μM. M2WJ332 completely inhibits plaque formation by the influenza A virus carrying the M2S31N mutant. M2WJ332 is applicable to research related to influenza A virus infection.

Lysyl-phenylalanyl-lysine (Compound KFK) is a tripeptide and belongs to the peptide segments related to thrombospondin-1 (TSP-1). Lysyl-phenylalanyl-lysine can activate LAP-TGF-β1 and release active TGF-β1, thereby inhibiting abnormal expression of MMP. Lysyl-phenylalanyl-lysine can be used for research on skin aging-related diseases and poor wound healing.

Lys-PEG3-BA is an EML4-ALK/EGFR PROTAC degrader with DC50 values of 1.32 and 19.66 μM for H3122 (EML4-ALK) and H1975 (EGFR-L858R/T790M) cells, respectively. Lys-PEG3-BA hinders proliferation via rewiring the ubiquitin- proteasome system in vitro. Lys-PEG3-BA can be used for non-small cell lung cancer research.

Lyso iGB3 is a glycosphingolipid.

Lycorine methiodide (N-Methyllycorine iodide) is a derivative of Lycorine. Lycorine methiodide exhibits no significant in vitro antitumor activity against A549, OE21, Hs683, U373, SKMEL, and B16F10 cell lines, with all IC50 values greater than 10 μM.